GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLight Life Sciences Ltd (NAS:BOLT) » Definitions » Enterprise Value

BioLight Life Sciences (BioLight Life Sciences) Enterprise Value : $267.91 Mil (As of Apr. 27, 2024)


View and export this data going back to . Start your Free Trial

What is BioLight Life Sciences Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BioLight Life Sciences's Enterprise Value is $267.91 Mil. BioLight Life Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.16 Mil. Therefore, BioLight Life Sciences's EV-to-EBIT ratio for today is -37.41.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, BioLight Life Sciences's Enterprise Value is $267.91 Mil. BioLight Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.02 Mil. Therefore, BioLight Life Sciences's EV-to-EBITDA ratio for today is -38.16.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, BioLight Life Sciences's Enterprise Value is $267.91 Mil. BioLight Life Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.03 Mil. Therefore, BioLight Life Sciences's EV-to-Revenue ratio for today is 8,642.29.


BioLight Life Sciences Enterprise Value Historical Data

The historical data trend for BioLight Life Sciences's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLight Life Sciences Enterprise Value Chart

BioLight Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioLight Life Sciences Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioLight Life Sciences's Enterprise Value

For the Biotechnology subindustry, BioLight Life Sciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLight Life Sciences's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLight Life Sciences's Enterprise Value distribution charts can be found below:

* The bar in red indicates where BioLight Life Sciences's Enterprise Value falls into.



BioLight Life Sciences Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

BioLight Life Sciences's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

BioLight Life Sciences's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLight Life Sciences  (NAS:BOLT) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

BioLight Life Sciences's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=267.911/-7.161
=-37.41

BioLight Life Sciences's current Enterprise Value is $267.91 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. BioLight Life Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.16 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

BioLight Life Sciences's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=267.911/-7.021
=-38.16

BioLight Life Sciences's current Enterprise Value is $267.91 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. BioLight Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.02 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

BioLight Life Sciences's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=267.911/0.031
=8,642.29

BioLight Life Sciences's current Enterprise Value is $267.91 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. BioLight Life Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLight Life Sciences Enterprise Value Related Terms

Thank you for viewing the detailed overview of BioLight Life Sciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLight Life Sciences (BioLight Life Sciences) Business Description

Traded in Other Exchanges
Address
Kiryat Atidim, Building 7, Entrance 1, 2nd Floor, Tel-Aviv, ISR, 6158101
BioLight Life Sciences Ltd is an emerging global ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.

BioLight Life Sciences (BioLight Life Sciences) Headlines

From GuruFocus

Bolt Biotherapeutics Appoints Laura Berner to Board of Directors

By Value_Insider Value_Insider 12-14-2022

Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference

By Value_Insider Value_Insider 11-01-2022